SURPASS trial programme: difference between revisions
Diff·revision 10 → 11·00:17, 26 Nov 2024
Difference between revision 10 and revision 11 of SURPASS trial programme. 1 line changed; the page grew by 34 bytes.
| Revision 10 — 23:29, 5 Nov 2024 TrialsTabitha (talk) state that the trial has reported but is not yet peer-reviewed 3,627 bytes +1,016 | Revision 11 — 00:17, 26 Nov 2024 GastroparesisGwen (talk) cite the trial publication rather than the sponsor press release 3,661 bytes +34 | ||
|---|---|---|---|
| 1 | {{Infobox concept | 1 | {{Infobox concept |
| 2 | | name = SURPASS trial programme | 2 | | name = SURPASS trial programme |
| + | 3 | | subtitle = Phase 3 programme | |
| 3 | | Drug = [[Tirzepatide|Tirzepatide]] 5, 10 and 15 mg weekly | 4 | | Drug = [[Tirzepatide|Tirzepatide]] 5, 10 and 15 mg weekly |
| 4 | | Indication = Type 2 diabetes | 5 | | Indication = Type 2 diabetes |